A detailed history of Vanguard Group Inc transactions in Pulmonx Corp stock. As of the latest transaction made, Vanguard Group Inc holds 2,077,859 shares of LUNG stock, worth $13.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,077,859
Previous 2,066,442 0.55%
Holding current value
$13.2 Million
Previous $26.3 Million 26.89%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$8.71 - $14.65 $99,442 - $167,259
11,417 Added 0.55%
2,077,859 $19.3 Million
Q4 2023

Feb 14, 2024

BUY
$7.89 - $13.14 $336,161 - $559,842
42,606 Added 2.11%
2,066,442 $26.3 Million
Q3 2023

Nov 14, 2023

BUY
$9.88 - $14.0 $191,316 - $271,096
19,364 Added 0.97%
2,023,836 $20.9 Million
Q2 2023

Aug 14, 2023

SELL
$10.78 - $13.65 $6.37 Million - $8.06 Million
-590,541 Reduced 22.76%
2,004,472 $26.3 Million
Q1 2023

May 15, 2023

BUY
$7.49 - $12.54 $1.31 Million - $2.2 Million
175,393 Added 7.25%
2,595,013 $29 Million
Q4 2022

Feb 10, 2023

SELL
$4.92 - $17.35 $3.6 Million - $12.7 Million
-732,122 Reduced 23.23%
2,419,620 $20.4 Million
Q3 2022

Nov 14, 2022

BUY
$15.35 - $23.99 $279,861 - $437,385
18,232 Added 0.58%
3,151,742 $52.5 Million
Q2 2022

Aug 12, 2022

BUY
$14.0 - $27.95 $7.24 Million - $14.4 Million
516,991 Added 19.76%
3,133,510 $46.1 Million
Q1 2022

May 13, 2022

BUY
$21.13 - $35.65 $1.94 Million - $3.28 Million
92,031 Added 3.65%
2,616,519 $64.9 Million
Q4 2021

Feb 14, 2022

BUY
$29.72 - $45.1 $2.15 Million - $3.26 Million
72,373 Added 2.95%
2,524,488 $81 Million
Q3 2021

Nov 12, 2021

BUY
$35.98 - $44.48 $20.3 Million - $25.1 Million
563,840 Added 29.86%
2,452,115 $88.2 Million
Q2 2021

Aug 13, 2021

BUY
$37.61 - $48.0 $71 Million - $90.6 Million
1,888,275 New
1,888,275 $83.3 Million

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $236M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.